263 related articles for article (PubMed ID: 27327964)
21. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
22. Febrile urinary tract infections: pyelonephritis and urosepsis.
Schneeberger C; Holleman F; Geerlings SE
Curr Opin Infect Dis; 2016 Feb; 29(1):80-5. PubMed ID: 26658652
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
Arakawa S; Kawahara K; Kawahara M; Yasuda M; Fujimoto G; Sato A; Yokokawa R; Yoshinari T; Rhee EG; Aoyama N
J Infect Chemother; 2019 Feb; 25(2):104-110. PubMed ID: 30420153
[TBL] [Abstract][Full Text] [Related]
24. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
25. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Murri R; Sacco E
Expert Opin Pharmacother; 2021 Aug; 22(11):1377-1379. PubMed ID: 33849371
[No Abstract] [Full Text] [Related]
26. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
27. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
[TBL] [Abstract][Full Text] [Related]
28. Ceftolozane/tazobactam: place in therapy.
Giacobbe DR; Bassetti M; De Rosa FG; Del Bono V; Grossi PA; Menichetti F; Pea F; Rossolini GM; Tumbarello M; Viale P; Viscoli C;
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):307-320. PubMed ID: 29493397
[TBL] [Abstract][Full Text] [Related]
29. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
31. Infection: Ceftolozane-tazobactam gives a new ASPECT to the fight against antimicrobial resistance.
Edwards JK
Nat Rev Urol; 2015 Jun; 12(6):306. PubMed ID: 25963963
[No Abstract] [Full Text] [Related]
32. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Velez Perez AL; Schmidt-Malan SM; Kohner PC; Karau MJ; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):356-359. PubMed ID: 27130477
[TBL] [Abstract][Full Text] [Related]
33. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Shortridge D; Castanheira M; Pfaller MA; Flamm RK
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
[TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Farrell DJ; Sader HS; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
[TBL] [Abstract][Full Text] [Related]
35. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Popa C; Mircheva M; Krämer BK; Berghofen A; Krüger B
Lancet; 2015 Sep; 386(10000):1241-1242. PubMed ID: 26460657
[No Abstract] [Full Text] [Related]
36. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Kielstein JT; Schmidt JJ
Lancet; 2015 Sep; 386(10000):1241. PubMed ID: 26460656
[No Abstract] [Full Text] [Related]
37. Ceftolozane-tazobactam versus levofloxacin in urinary tract infection.
Boyles T
Lancet; 2015 Sep; 386(10000):1241. PubMed ID: 26460655
[No Abstract] [Full Text] [Related]
38. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
Martin-Loeches I; Bruno CJ; DeRyke CA
Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
[TBL] [Abstract][Full Text] [Related]
39. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP
Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
